Literature DB >> 21861175

[In vitro diagnosis and monitoring of Hymenoptera venom hyposensitization].

M M Neis1, G Wurpts, L Wilbers, H F Merk.   

Abstract

Specific immunotherapy (SIT) of hymenoptera venom allergy, in particular, has become an example for the effectiveness of the treatment of IgE-mediated allergic diseases. In vitro diagnostic procedures and the measurement of serum tryptase for risk assessment are well-established in the process of diagnose finding and therapy preparation. For monitoring and validation of the effectiveness of the SIT, however, in vitro diagnostic procedures remain controversial. Potentially useful approaches include detection of specific IgE, specific IgG4, basophile activation - represented by the CD 63 expression - and the lymphocyte proliferation and its IL10 release. Preliminary data suggest that the latter method appear appropriate, whereas the detection of basophile activation did not produce definite results.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21861175     DOI: 10.1007/s00105-011-2160-7

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  26 in total

1.  Added value of IgE detection to rApi m 1 and rVes v 5 in patients with Hymenoptera venom allergy.

Authors:  Silke C Hofmann; Nikolai Pfender; Steffi Weckesser; Johannes Huss-Marp; Thilo Jakob
Journal:  J Allergy Clin Immunol       Date:  2010-08-16       Impact factor: 10.793

2.  Flow-assisted quantification of in vitro activated basophils in the diagnosis of wasp venom allergy and follow-up of wasp venom immunotherapy.

Authors:  D G Ebo; M M Hagendorens; A J Schuerwegh; L M-N Beirens; C H Bridts; L S De Clerck; W J Stevens
Journal:  Cytometry B Clin Cytom       Date:  2007-05       Impact factor: 3.058

3.  Inhibition of human allergic T-helper type 2 immune responses by induced regulatory T cells requires the combination of interleukin-10-treated dendritic cells and transforming growth factor-beta for their induction.

Authors:  I Bellinghausen; B König; I Böttcher; J Knop; J Saloga
Journal:  Clin Exp Allergy       Date:  2006-12       Impact factor: 5.018

4.  Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy.

Authors:  E Mamessier; J Birnbaum; P Dupuy; D Vervloet; A Magnan
Journal:  Clin Exp Allergy       Date:  2006-06       Impact factor: 5.018

5.  Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.

Authors:  Franziska Ruëff; Bernhard Przybilla; Maria Beatrice Biló; Ulrich Müller; Fabian Scheipl; Werner Aberer; Joëlle Birnbaum; Anna Bodzenta-Lukaszyk; Floriano Bonifazi; Christoph Bucher; Paolo Campi; Ulf Darsow; Cornelia Egger; Gabrielle Haeberli; Thomas Hawranek; Iwona Kucharewicz; Helmut Küchenhoff; Roland Lang; Oliviero Quercia; Norbert Reider; Maurizio Severino; Michael Sticherling; Gunter Johannes Sturm; Brunello Wüthrich
Journal:  J Allergy Clin Immunol       Date:  2010-06-12       Impact factor: 10.793

Review 6.  IL-10-producing type 1 regulatory T cells and allergy.

Authors:  Kui Wu; Yutian Bi; Kun Sun; Changzheng Wang
Journal:  Cell Mol Immunol       Date:  2007-08       Impact factor: 11.530

Review 7.  Regulatory T cells in allergy and asthma.

Authors:  Mark Larché
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

8.  Role of interleukin 10 in specific immunotherapy.

Authors:  C A Akdis; T Blesken; M Akdis; B Wüthrich; K Blaser
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

9.  Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells.

Authors:  M Pierkes; I Bellinghausen; T Hultsch; G Metz; J Knop; J Saloga
Journal:  J Allergy Clin Immunol       Date:  1999-02       Impact factor: 10.793

10.  Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals.

Authors:  H Secrist; C J Chelen; Y Wen; J D Marshall; D T Umetsu
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.